The automation of cell therapy processing or manufacturing systems has provided significant advantages to the worldwide pharmaceutical industry. The process of manufacturing cell treatments involves several processes, including the selection, isolation, modification, and expansion of cells. Even a slight miscalculation in this intricate process could result in the incorrect administration of cells. The utilization of automated and closed-cell therapy processing methods reduces the level of risk associated with the final formulation. Automation decreases the likelihood of contamination caused by manual manipulation in cell treatment.
Rising Emphasis on Regenerative Medicines and Cell Therapies Drives the Global Market
Regenerative medicine is essential for the replacement of damaged cells and tissues through the use of stem cells, molecules, and various biomaterials. Knowledge and understanding of this emerging discipline are growing as a result of its exceptional results and efficacy. Additionally, these cells can serve as vehicles for gene and cultured cell therapy. Hence, the increasing recognition of regenerative medications is anticipated to elevate the need for stem cell therapies. This would ultimately stimulate the demand for automated and closed-cell therapy processing systems, hence propelling market expansion.
Furthermore, numerous prominent biopharmaceutical companies have recognized the vast potential of regenerative medicine technologies in addressing clinical scenarios and disease indications where there is a lack of effective medical treatment due to the constraints of the current standard of care. Corporations are employing various strategies, such as mergers and acquisitions, to overcome this challenge. These methods aim to expand their product offerings and rejuvenate and enhance their pipelines within this industry.
Increasing Technological Advancements Creates Tremendous Opportunities
The proliferation of technological breakthroughs is anticipated to favor the adoption and approval of automated and closed-cell therapy processing systems. The global market is anticipated to experience an increase in the number of product approvals and product launches due to the rising demand for high-throughput and the growing number of clinical trials for cell treatments. Miltenyi Biotec introduced its innovative CliniMACS Prodigy Adherent Cell Culture System in July 2020. The recently implemented method has the ability to efficiently and automatically produce a wide range of cell types, including stem cells, on a large scale.
In addition, Terumo Corporation announced in October 2019 the introduction of a state-of-the-art system designed to expedite cell therapy production. The recently implemented technology has the ability to improve the manufacturing and distribution of gene and cell therapies.
North America is the most significant global automated and closed cell therapy processing systems shareholder and is anticipated to exhibit a CAGR of 21.70% during the forecast period. The significant market expansion can be attributed to the increasing participation of enterprises in the research and development of cell treatments. The market expansion is due to the proliferation of numerous institutes and centers engaged in cell therapy production. Moreover, the market growth is driven by strong government support, the presence of important industry players, and strategic efforts to expand the market.
In June 2020, ThermoGenesis Holdings, Inc. and Corning Incorporated's Life Sciences Division established a worldwide distribution agreement for their X-SERIES products. Artiva Biopharmaceuticals disclosed its plans to broaden its presence in the United States by establishing state-of-the-art research and development and a manufacturing facility specifically dedicated to cell treatments in August 2021.
The key players in the global automated and closed cell therapy processing systems market are Thermo Fisher Scientific, Lonza, Cytiva (Danaher), Terumo Corporation, Fresenius Kabi, ThermoGenesis Holdings, Inc., Sartorius AG, Cellares, Inc., BioSpherix, Ltd., STEMCELL Technologies, Inc., Corning Incorporated, Merck KGaA, and Tomtec.